This week, Bobbi Conner talks with MUSC's Dr. Christina Mingora about the impact of recent advances in treating cystic ...

Camilla Bell, M.Sc., Ph.D., an assistant professor in the UAB Department of Pathology’s Division of Molecular and Cellular Pathology, has been awarded a grant by Vertex Pharmaceuticals as part of the ...

Care for patients with cystic fibrosis has undergone transformative changes over the past decade and serves as an example of how an understanding of the functional consequences of a genetic disease ...

Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

The European Medicines Agency (EMA) recommended in its April meetings approval of marketing authorizations for two orphan medicines: Alyftrek for the treatment of cystic fibrosis and Attrogy for the ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated disease that differs from person to person. An autosomal recessive disorder ...

Breathing disorders are common in the U.S. with conditions like COPD affecting some 7% of the population and asthma affecting another 10%. Digestive conditions like GERD, acid reflux, Celiac disease ...